Geneva Capital Management LLC Lowers Holdings in Axon Enterprise, Inc $AXON

Geneva Capital Management LLC decreased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 5.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,002 shares of the biotechnology company’s stock after selling 4,690 shares during the period. Geneva Capital Management LLC owned 0.10% of Axon Enterprise worth $56,695,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. NEOS Investment Management LLC increased its holdings in shares of Axon Enterprise by 82.7% in the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after purchasing an additional 11,482 shares during the last quarter. Vanguard Group Inc. grew its holdings in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in Axon Enterprise by 3.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after buying an additional 5,953 shares in the last quarter. BIT Capital GmbH increased its stake in Axon Enterprise by 75.6% in the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock worth $2,537,000 after acquiring an additional 1,522 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC raised its holdings in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after acquiring an additional 775 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

AXON opened at $529.97 on Wednesday. The business has a fifty day moving average of $534.81 and a 200 day moving average of $613.75. The stock has a market cap of $42.61 billion, a P/E ratio of 348.67, a PEG ratio of 11.93 and a beta of 1.46. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 52-week low of $396.41 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The business’s revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.08 earnings per share. As a group, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Analysts and market pieces note AXON’s strong recent momentum and demand — the stock has climbed ~28–29% over the past month on robust device and software uptake, which supports the company’s multi-year growth narrative. Axon Stock Rises 28.6% in a Month
• Positive Sentiment: Zacks highlights earnings growth and price strength as reasons AXON remains a stock to watch, reinforcing the view that recent results (revenue and EPS beats) underpin upside expectations. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: Coverage referencing AppLovin’s “AXON” product (AppLovin’s AXON 2.0 ad engine and related studies) is generating industry attention but refers to a different company/product; this can create headline noise and investor confusion rather than direct fundamental impact on Axon Enterprise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Neutral Sentiment: Related AppLovin/marketing partnership and Kantar report items (which reference “Axon by AppLovin”) and Bank of America commentary on AppLovin add sector-level noise but are not company-specific catalysts for AXON. Mobile Gaming Now a Mainstream Consumer Channel Driving Purchase Impact for Brands Bank of America Reaffirms Buy on AppLovin
• Neutral Sentiment: Short-interest notices in recent feeds show anomalous/zero values and NaN changes — the published short data looks unreliable and is unlikely to be a meaningful immediate driver. (No reliable short-covering signal shown.)
• Negative Sentiment: Market reaction today looks driven by profit-taking after the post-earnings run-up and valuation sensitivity; QuiverQuant notes AXON slid as investors digested a rich valuation and a lack of fresh company-specific catalysts. Insider selling activity (multiple recent sales reported) also adds to near-term caution. Axon slips as investors digest rich valuation
• Negative Sentiment: Relative-performance coverage flags that AXON is underperforming some peers today — a reminder investors are rotating within the sector and favoring names with more attractive near-term risk/reward. Axon Enterprise Inc. stock underperforms Tuesday

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a research report on Tuesday, January 6th. Royal Bank Of Canada lowered their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. Wall Street Zen raised Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Citigroup restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, Piper Sandler lowered their price objective on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Insider Activity at Axon Enterprise

In other news, CFO Brittany Bagley sold 2,000 shares of Axon Enterprise stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the completion of the sale, the chief financial officer owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. The trade was a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the sale, the chief executive officer directly owned 3,090,997 shares of the company’s stock, valued at $1,546,240,339.28. This represents a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 26,634 shares of company stock worth $14,963,095. 5.70% of the stock is currently owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.